HCHugo Ceulemans

Hugo Ceulemans

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hugo Ceulemans has a total of 365 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Low concentration cell painting images enable the identification of highly potent compounds

    by Son V. Ha, Steffen Jaensch, Lorena G. A. Freitas, Dorota Herman, Paul Czodrowski, Hugo Ceulemans

    Image-based models that use features extracted from cell microscopy images can estimate the activity of small molecules in various biological assays. Typically, models are trained on images stained by an optimized protocol (e.g. Cell Painting) after exposure to a fairly high small molecule concentration (referred to as ’image concentration’) of $$10\; \upmu {\text{M}}$$ 10 μ M or higher. Low concentration images (e.g. $$0.16$$ 0.16 μM, $$0.8$$ 0.8 μM, $$4$$ 4 μM) tend to yield models with worse performance. In this work, we nevertheless report a practical use for low image concentration data. We propose the combination of well-performing models trained at higher image concentrations, with lower image concentration for inference to identify more potent compounds. We show that this approach improves on the conventional method (directly training a high-potency model) in 65 $$\%$$ % of assays investigated in terms of AUC-ROC, and 75 $$\%$$ % of assays in terms of RIPtoP-corrected AUC-PR.


  • Open Access

    Balancing Imbalanced Toxicity Models: Using MolBERT with Focal Loss

    by Muhammad Arslan Masood, Samuel Kaski, Hugo Ceulemans, Dorota Herman, Markus Heinonen

    Drug-induced liver injury (DILI) presents a multifaceted challenge, influenced by interconnected biological mechanisms. Current DILI datasets are characterized by small sizes and high imbalance, posing difficulties in learning robust representations and accurate modeling. To address these challenges, we trained a multi-modal multi-task model integrating preclinical histopathologies, biochemistry (blood markers), and clinical DILI-related adverse drug reactions (ADRs). Leveraging pretrained BERT models, we extracted representations covering a broad chemical space, facilitating robust learning in both frozen and fine-tuned settings. To address imbalanced data, we explored weighted Binary Cross-Entropy (w-BCE) and weighted Focal Loss (w-FL) . Our results demonstrate that the frozen BERT model consistently enhances performance across all metrics and modalities with weighted loss functions compared to their non-weighted counterparts. However, the efficacy of fine-tuning BERT varies across modalities, yielding inconclusive results. In summary, the incorporation of BERT features with weighted loss functions demonstrates advantages, while the efficacy of fine-tuning remains uncertain.

  • Open Access

    Aquamarine: Quantum-Mechanical Exploration of Conformers and Solvent Effects in Large Drug-like Molecules

    by Leonardo Rafael Medrano Sandonas, Dries Van Rompaey, Alessio Fallani, Mathias Hilfiker, David Hahn, Laura Perez-Benito, Jonas Verhoeven, Gary Tresadern, Joerg Kurt Wegner, Hugo Ceulemans, et al.

    We here introduce the Aquamarine (AQM) dataset, an extensive quantum-mechanical (QM) dataset that contains the structural and electronic information of 59,783 low-and high-energy conformers of 1,653 molecules with a total number of atoms ranging from 2 to 92 (mean:50.9), and containing up to 54 (mean:28.2) non-hydrogen atoms. To gain insights into the solvent effects as well as collective dispersion interactions for drug-like molecules, we have performed QM calculations supplemented with a treatment of many-body dispersion (MBD) interactions of structures and properties in the gas phase and implicit water. Thus, AQM contains over 40 global (molecular) and local (atom-in-a-molecule) physicochemical properties (including ground-state and response properties) per conformer computed at the tightly converged PBE0+MBD level of theory for gas-phase molecules, whereas PBE0+MBD with the modified Poisson-Boltzmann (MPB) model of water was used for solvated molecules. By addressing both molecule-solvent and dispersion interactions, AQM dataset can serve as a challenging benchmark for state-of-the-art machine learning methods for property modeling and \textit{de novo} generation of large (solvated) molecules with pharmaceutical and biological relevance.

  • Top Cited Papers
    Open Access

    MELLODDY: Cross-pharma Federated Learning at Unprecedented Scale Unlocks Benefits in QSAR without Compromising Proprietary Information

    by Wouter Heyndrickx, Lewis Mervin, Tobias Morawietz, Noé Sturm, Lukas Friedrich, Adam Zalewski, Anastasia Pentina, Lina Humbeck, Martijn Oldenhof, Ritsuya Niwayama, et al.

    Federated multipartner machine learning has been touted as an appealing and efficient method to increase the effective training data volume and thereby the predictivity of models, particularly when the generation of training data is resource-intensive. In the landmark MELLODDY project, indeed, each of ten pharmaceutical companies realized aggregated improvements on its own classification or regression models through federated learning. To this end, they leveraged a novel implementation extending multitask learning across partners, on a platform audited for privacy and security. The experiments involved an unprecedented cross-pharma data set of 2.6+ billion confidential experimental activity data points, documenting 21+ million physical small molecules and 40+ thousand assays in on-target and secondary pharmacodynamics and pharmacokinetics. Appropriate complementary metrics were developed to evaluate the predictive performance in the federated setting. In addition to predictive performance increases in labeled space, the results point toward an extended applicability domain in federated learning. Increases in collective training data volume, including by means of auxiliary data resulting from single concentration high-throughput and imaging assays, continued to boost predictive performance, albeit with a saturating return. Markedly higher improvements were observed for the pharmacokinetics and safety panel assay-based task subsets.


  • Open Access

    JUMP Cell Painting chemical dataset: Morphological map of 115,796 compounds in human cells

    by Srinivas Niranj Chandrasekaran, Jeanelle Ackerman, Eric Alix, D. Michael Ando, John Arevalo, Melissa Bennion, Nicolas Boisseau, Adriana Borowa, Justin D. Boyd, Laurent Brino, et al.

    Image-based profiling decodes complex cellular states for high-impact biological and therapeutic applications, yet a large, public reference dataset of chemical perturbations has been lacking. We present Cell Painting images and 1.53 billion single-cell profiles for 115,796 compounds in human osteosarcoma cells, generated by the Joint Undertaking for Morphological Profiling (JUMP)-Cell Painting Consortium of 18 industry and non-profit partners. Despite technical variability across 12 data-generating laboratories, more than 15% of compounds show statistically significant phenotypic activity, reproducibility drops only 34% versus single-laboratory data, and compounds sharing biological targets often show similar image-based profiles. JUMP establishes a validated public reference resource that brings image-based profiling on par with genomics and transcriptomics. The dataset, shared alongside previously released genetic perturbation data in the Cell Painting Gallery, is a powerful predictive engine for the impact, mechanism, targets and activities of compounds, fundamentally accelerating chemical and cell biology and early-stage drug development.


  • Open Access

    Industry-Scale Orchestrated Federated Learning for Drug Discovery

    by Martijn Oldenhof, Gergely Ács, Balázs Pejó, Ansgar Schuffenhauer, Nicholas Holway, Noé Sturm, Arne Dieckmann, Oliver Fortmeier, Eric Boniface, Clément Mayer, et al.

    To apply federated learning to drug discovery we developed a novel platform in the context of European Innovative Medicines Initiative (IMI) project MELLODDY (grant n{\deg}831472), which was comprised of 10 pharmaceutical companies, academic research labs, large industrial companies and startups. The MELLODDY platform was the first industry-scale platform to enable the creation of a global federated model for drug discovery without sharing the confidential data sets of the individual partners. The federated model was trained on the platform by aggregating the gradients of all contributing partners in a cryptographic, secure way following each training iteration. The platform was deployed on an Amazon Web Services (AWS) multi-account architecture running Kubernetes clusters in private subnets. Organisationally, the roles of the different partners were codified as different rights and permissions on the platform and administrated in a decentralized way. The MELLODDY platform generated new scientific discoveries which are described in a companion paper.


  • Open Access

    Development and Implementation of an enterprise-wide Predictive Model for Early absorption, distribution, Metabolism and Excretion Properties

    by Kiran Kumar, Vladimir Chupakhin, Ann Vos, Denise Morrison, Dmitrii Rassokhin, Martin J Dellwo, Keith McCormick, Eric Paternoster, Hugo Ceulemans, Renee L DesJarlais

    Background: Accurate prediction of absorption, distribution, metabolism and excretion (ADME) properties can facilitate the identification of promising drug candidates. Methodology & Results: The au...


  • Open Access

    Tales of 1,008 Small Molecules: Phenomic Profiling through Live-cell Imaging in a Panel of Reporter Cell Lines

    by Michael J. Cox, Steffen Jaensch, Jelle Van de Waeter, Laure Cougnaud, Daan Seynaeve, Soulaiman Benalla, Seong Joo Koo, Ilse Van Den Wyngaert, Jean-Marc Neefs, Dmitry Malkov, et al.

    Phenomic profiles are high-dimensional sets of readouts that can comprehensively capture the biological impact of chemical and genetic perturbations in cellular assay systems. Phenomic profiling of compound libraries can be used for compound target identification or mechanism of action (MoA) prediction and other applications in drug discovery. To devise an economical set of phenomic profiling assays, we assembled a library of 1,008 approved drugs and well-characterized tool compounds manually annotated to 218 unique MoAs, and we profiled each compound at four concentrations in live-cell, high-content imaging screens against a panel of 15 reporter cell lines, which expressed a diverse set of fluorescent organelle and pathway markers in three distinct cell lineages. For 41 of 83 testable MoAs, phenomic profiles accurately ranked the reference compounds (AUC-ROC ≥0.9). MoAs could be better resolved by screening compounds at multiple concentrations than by including replicates at a single concentration. Screening additional cell lineages and fluorescent markers increased the number of distinguishable MoAs but this effect quickly plateaued. There remains a substantial number of MoAs that were hard to distinguish from others under the current study’s conditions. We discuss ways to close this gap, which will inform the design of future phenomic profiling efforts.


  • Fast semi-supervised discriminant analysis for binary classification of large data sets

    by Joris Tavernier, Jaak Simm, Karl Meerbergen, Joerg Kurt Wegner, Hugo Ceulemans, Yves Moreau


  • Top Cited Papers
    Open Access

    Large-scale comparison of machine learning methods for drug target prediction on ChEMBL

    by Andreas Mayr, Günter Klambauer, Thomas Unterthiner, Marvin Steijaert, Jörg K. Wegner, Hugo Ceulemans, Djork-Arné Clevert, Sepp Hochreiter

    Deep learning is currently the most successful machine learning technique in a wide range of application areas and has recently been applied successfully in drug discovery research to predict potential drug targets and to screen for active molecules. However, due to (1) the lack of large-scale studies, (2) the compound series bias that is characteristic of drug discovery datasets and (3) the hyperparameter selection bias that comes with the high number of potential deep learning architectures, it remains unclear whether deep learning can indeed outperform existing computational methods in drug discovery tasks. We therefore assessed the performance of several deep learning methods on a large-scale drug discovery dataset and compared the results with those of other machine learning and target prediction methods. To avoid potential biases from hyperparameter selection or compound series, we used a nested cluster-cross-validation strategy. We found (1) that deep learning methods significantly outperform all competing methods and (2) that the predictive performance of deep learning is in many cases comparable to that of tests performed in wet labs (i.e., in vitro assays).